Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

July 12, 2011 08:00 ET

Stem Cell Therapeutics Corp. Announces a Traumatic Brain Injury Presentation at National Neurotrauma Symposium 2011

CALGARY, ALBERTA--(Marketwire - July 12, 2011) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") announces the oral presentation of traumatic brain injury (TBI) research at the National Neurotrauma Symposium (NNS 2011) in Hollywood, Florida on July 12th, 2011 at 11:45 am. The oral presentation will be given by Dr. Ludmila Belayev of Louisiana State University and is entitled, "A Novel Therapeutic Strategy For Traumatic Brain Injury". This research abstract was submitted for peer review, and invited to be presented as an oral presentation.

The TBI study was designed to demonstrate that, in a controlled rodent model of fluid percussion injury, recovery of brain cellular integrity and function after TBI was improved by SCT's NTx-428 regimen in the treated group compared to placebo. As hypothesized prior to the initiation of this study, treatment with human chorionic gonadotropin (hCG) and then erythropoietin (EPO) administered 24 hours after moderate to severe TBI was observed to significantly decrease brain matter loss and improve functional recovery of symptoms. An unexpected and key new observation from this study was a substantial and significant increase in cell count number in the dentate gyrus region and specifically CA3 neuron population. Importantly, cell populations within the dentate gyrus and specifically CA neurons are thought to play a role in key memory functions in animals and man. Accompanying the maintenance of overall brain volume and these specific cell populations was a robust and statistically significant behavioral improvement which started after day 14 and that continued to improve beyond day 21.

In North America, moderate to severe TBI is a leading cause of cognitive and physical disability, and in excess of 1.4 million individuals suffer TBI each year. Of those, 300,000 individuals suffer sufficiently severe injury to be hospitalized. Individuals who present with moderate to severe neurological injuries often have symptoms that may persist as lifelong disabilities and include cognitive, speech, perceptual, memory, sensory, social-emotional or motor deficits.

"The research presented today at this prestigious meeting of leading neuroscientists shows, for the first time, the discovery that treatment with a regimen of hCG, followed by EPO positively impacts recovery of hippocampal neuron populations within the dentate gyrus, a region of the brain, during recovery from moderate to severe TBI. The hippocampus is an area widely accepted to play an important role in memory function as well as spacial navigation. Within the hippocampus the dentate gyrus and its accompanying CA3 neurons are one of the richest sources of stem cells in the brain." said Dr. Allen Davidoff, Chief Scientific Officer for Stem Cell Therapeutics Corp. "We are encouraged by the positive results in this rodent model of moderate to severe brain injury and the statistically significant recovery of CA neuron and dentate gyrus cell populations. This animal experiment importantly suggests a new avenue to explore in our ongoing human clinical TBI studies at the Foothills Hospital & University of Calgary under the guidance of Dr. David Zygun."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE:SSS) developing and commercializing drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information